tiprankstipranks
OKYO Pharma Limited Sponsored ADR (OKYO)
NASDAQ:OKYO
US Market

OKYO Pharma Limited Sponsored ADR (OKYO) Income Statement

31 Followers

OKYO Pharma Limited Sponsored ADR Income Statement

Last quarter (Q2 2023), OKYO Pharma Limited Sponsored ADR's total revenue was £―, a decrease of ― from the same quarter last year. In Q2, OKYO Pharma Limited Sponsored ADR's net income was £―. See OKYO Pharma Limited Sponsored ADR’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Mar 22Mar 21Mar 20Mar 19Mar 18
Total Revenue
---£ 0.00£ 0.00£ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
--£ 2.45M£ 1.21M£ 3.48M£ 743.93K
Operating Income
--£ -2.45M£ -1.21M£ -3.48M£ -743.93K
Net Non Operating Interest Income Expense
--£ 817.00£ 36.94K£ 0.00£ 0.00
Other Income Expense
--£ -8.13K---
Pretax Income
-£ -4.55M£ -2.46M£ -1.27M£ -3.76M£ -20.17M
Tax Provision
-£ -575.87K£ -18.18K£ -60.00K£ 0.00£ 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-£ -3.98M£ -2.44M£ -1.21M£ -3.76M£ -20.17M
Basic EPS
--£ -0.01---
Diluted EPS
--£ -0.01---
Basic Average Shares
-£ 979.21M£ 672.77M---
Diluted Average Shares
-£ 979.21M£ 672.82M---
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
----£ 2.86K£ 0.00
Total Expenses
--£ -2.45M£ 1.21M£ 3.48M£ 743.93K
Net Income From Continuing And Discontinued Operation
-£ -3.98M£ -2.44M£ -1.21M£ -3.76M£ -20.17M
Normalized Income
-£ -5.13M£ -2.46M£ -1.11M£ -3.48M£ -752.80K
Interest Expense
---£ 911.00£ 0.00-
EBIT
--£ -2.46M£ -1.27M£ -3.76M£ -743.93K
EBITDA
--£ -2.46M£ -1.27M£ -3.76M£ -743.93K
Currency in GBP

OKYO Pharma Limited Sponsored ADR Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis